Abstract
We previously showed that downregulation of the urokinase-type plasminogen activator receptor (uPAR) in the SNB19 human glioblastoma cell line by the stable transfection of a plasmid expressing a 300 bp antisense sequence to the 5′ end of the uPAR gene produced a decrease in the amount of target mRNA. In a more recent study, we found that adenovirus-mediated transduction (Ad-uPAR) of the same uPAR antisense gene construct in SNB19 cells also downregulated uPAR protein levels. We report here that Ad-uPAR-transfected SNB19 cells produced the same amounts of target uPAR mRNA but significantly less protein by in vitro translation and by in situ [35S] labeling compared to Ad-CMV vector-transfected and mock-transfected cells. This antisense construct also inhibited glioblastoma cell invasion confirming previous results. We conclude that downregulation of uPAR by this antisense gene construct results from inhibition of protein translation.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Mignatti P, Rifkin DB. Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 1993; 73: 161–95.
Murphy G, Atkinson S, Ward R et al. The role of plasminogen activators in the regulation of connective tissue metalloproteinases. Ann NY Acad Sci 1992; 667: 1–12.
Vassalli JD, Baccino D, Belin DAJ. A cellular binding site for the Mr 55,000 form of human plasminogen activator, urokinase. J Cell Biol 1985; 100: 86–92.
Pollanen J, Stephens RW, Vaheri A. Directed plasminogen activation at the surface of normal and malignant cells. Adv Cancer Res 1991; 57: 273–328.
Behrendt N, Ronne E, Ploug M et al. The human receptor for urokinase plasminogen activator. NH2-terminal amino acid sequence and glycosylation variants. J Biol Chem 1990; 265: 6453–60.
Andreasen PA, Kjoller L, Christensen L, Duffy MJ. The urokinasetype plasminogen activator system in cancer metastasis: A review. Int J Cancer 1997; 72: 1–22.
Yamamoto M, Sawaya R, Mohanam S et al. Expression and localization of urokinase-type plasminogen activator receptor in human gliomas. Cancer Res 1994; 54: 5016–20.
Mohanam S, Sawaya R, McCutcheon I et al. Modulation of in vitro invasion of human glioblastoma cells by urokinase-type plasminogen activator receptor antibody. Cancer Res 1993; 53: 4143–7.
Gladson CL, Pijuan-Thompson V, Olman et al. Upregulation of urokinase and urokinase receptor genes in malignant astrocytoma. Am J Pathol 1995; 146: 1150–60.
Blaese RM. Gene therapy for cancer. Scientific American 1997; 276: 111–5.
Helene C, Toulme JJ. Specific regulation of gene expression by antisense, sense and antigene nucleic acids. Biochim Biophys Acta 1990; 1049: 99–125.
Mohanam S, Chintala SK, Go Y et al. In vitro inhibition of human glioblastoma cell line invasiveness by antisense uPA receptor. Oncogene 1997; 14: 1351–9.
Mohan PM, Chintala SK, Mohanam S et al. Adenovirus-mediated delivery of antisense gene to urokinase-type plasminogen activator receptor suppresses glioma invasion and tumor growth. Cancer Res 1999; 59: 3369–73.
Graham FL, Prevec L. Manipulation of adenovirus vectors. In Murray EJ (ed): Methods in Molecular Biology. Clifton: Humana Press 1991; Vol. 7; 109–27.
Chintala SK, Fueyo J, Gomez-Manzano C et al. Adenovirus-mediated p16/CDKN2 gene transfer suppresses glioma invasion in vitro. Oncogene 1997; 15: 2049–57.
Li H, Lu H, Griscelli F et al. Adenovirus-mediated delivery of a uPA/uPAR antagonist suppresses angiogenesis-dependent tumor growth and dissemination in mice. Gene Therapy 1998; 5: 1105–13.
Aznavoorian S, Murphy AN, Stetler-Stevenson WG, Liotta LA. Molecular aspects of tumor cell invasion and metastasis. Cancer 1993; 71: 1368–83.
Ellis V, Pyke C, Eriksen J, Solgerg H, Danø K. The urokinase receptor involvement in cell surface protolysis and cancer invasion. Ann NY Acad Sci 1992; 667: 13–31.
Stahl A, Mueller BM. Binding of urokinase to its receptor promotes migration and invasion of human melanoma cells in vitro. Cancer Res 1994; 54; 3066–77.
Weiss B, Davidkova G, Zhang SP. Antisense strategies in Neurobiology Neurochemistry Int 1997; 31: 321–48.
Sun FY, Faden AI. Pretreatment with antisense oligodeoxynucleotides directed against the NMDA-R1 receptor enhances survival and behavioral recovery following traumatic brain injury in rats. Brain Res 1995; 693: 163–8.
Wahlestedt C, Golanov E, Yamamoto S et al. Antisense oligodeoxynucleotides to NMDA-R1 receptor channel protect cortical neurons from excitotoxicity and reduce focal ischemic infarctions. Nature 1993; 363: 260–3.
Hulsey MG, Pless CM, White BD, Martin RJ. ICV administration of anti-NPY antisense oligonucleotide: effects on feeding behavior, body weight, peptide content and peptide release. Regul Pept 1995; 59: 207–14.
Arndt GM, Rank GH. Colocalization of antisense RNAs and ribozymes with their target mRNAs. Genome 1997; 40: 785–97.
Landgraf R, Gerstberger R, Montkwoski A et al. VI Vasopressin receptor antisense oligonucleotide into septum reduces vasopressin binding, social discrimination abilities, and anxiety-related behavior in rats. J Neurosci 1995; 15: 4250–8.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mohan, P.M., Lakka, S.S., Mohanam, S. et al. Downregulation of the urokinase-type plasminogen activator receptor through inhibition of translation by antisense oligonucleotide suppresses invasion of human glioblastoma cells. Clin Exp Metastasis 17, 617–621 (1999). https://doi.org/10.1023/A:1006779902978
Issue Date:
DOI: https://doi.org/10.1023/A:1006779902978